BACKGROUND AND PURPOSE: The negative affective states of withdrawal involve the recruitment of brain and peripheral stress circuitry [noradrenergic activity, induction of the hypothalamic-pituitary-adrenocortical (HPA) axis and activation of heat shock proteins (Hsps)]. Corticotropin-releasing factor (CRF) pathways are important mediators in the negative symptoms of opioid withdrawal. We performed a series of experiments to characterize the role of the CRF₁ receptor in the response of stress systems to morphine withdrawal and its effect in the heart using genetically engineered mice lacking functional CRF₁ receptors. EXPERIMENTAL APPROACH: Wild-type and CRF₁ receptor-knockout mice were treated with increasing doses of morphine. Precipitated withdrawal was induced by naloxone. Plasma adrenocorticotropic hormone (ACTH) and corticosterone levels, the expression of myocardial Hsp27, Hsp27 phosphorylated at Ser⁸², membrane (MB)- COMT, soluble (S)-COMT protein and NA turnover were evaluated by RIA, immunoblotting and HPLC. KEY RESULTS: During morphine withdrawal we observed an enhancement of NA turnover in parallel with an increase in mean arterial blood pressure (MAP) and heart rate (HR) in wild-type mice. In addition, naloxone-precipitated morphine withdrawal induced an activation of HPA axis and Hsp27. The principal finding of the present study was that plasma ACTH and corticosterone levels, MB-COMT, S-COMT, NA turnover, and Hsp27 expression and activation observed during morphine withdrawal were significantly inhibited in the CRF₁ receptor-knockout mice. CONCLUSION AND IMPLICATIONS: Our results demonstrate that CRF/CRF₁ receptor activation may contribute to stress-induced cardiovascular dysfunction after naloxone-precipitated morphine withdrawal and suggest that CRF/CRF₁ receptor pathways could contribute to cardiovascular disease associated with opioid addiction.
BACKGROUND AND PURPOSE: The negative affective states of withdrawal involve the recruitment of brain and peripheral stress circuitry [noradrenergic activity, induction of the hypothalamic-pituitary-adrenocortical (HPA) axis and activation of heat shock proteins (Hsps)]. Corticotropin-releasing factor (CRF) pathways are important mediators in the negative symptoms of opioid withdrawal. We performed a series of experiments to characterize the role of the CRF₁ receptor in the response of stress systems to morphine withdrawal and its effect in the heart using genetically engineered mice lacking functional CRF₁ receptors. EXPERIMENTAL APPROACH: Wild-type and CRF₁ receptor-knockout mice were treated with increasing doses of morphine. Precipitated withdrawal was induced by naloxone. Plasma adrenocorticotropic hormone (ACTH) and corticosterone levels, the expression of myocardial Hsp27, Hsp27 phosphorylated at Ser⁸², membrane (MB)- COMT, soluble (S)-COMT protein and NA turnover were evaluated by RIA, immunoblotting and HPLC. KEY RESULTS: During morphine withdrawal we observed an enhancement of NA turnover in parallel with an increase in mean arterial blood pressure (MAP) and heart rate (HR) in wild-type mice. In addition, naloxone-precipitated morphine withdrawal induced an activation of HPA axis and Hsp27. The principal finding of the present study was that plasma ACTH and corticosterone levels, MB-COMT, S-COMT, NA turnover, and Hsp27 expression and activation observed during morphine withdrawal were significantly inhibited in the CRF₁ receptor-knockout mice. CONCLUSION AND IMPLICATIONS: Our results demonstrate that CRF/CRF₁ receptor activation may contribute to stress-induced cardiovascular dysfunction after naloxone-precipitated morphine withdrawal and suggest that CRF/CRF₁ receptor pathways could contribute to cardiovascular disease associated with opioid addiction.
Authors: Zhaokan Yuan; Roy McCauley; Carol Chen-Scarabelli; Kadija Abounit; Anastasis Stephanou; Sean P Barry; Richard Knight; Samuel F Saravolatz; Louis D Saravolatz; Berkin O Ulgen; Gabriele M Scarabelli; Giuseppe Faggian; Alessandro Mazzucco; Louis Saravolatz; Tiziano M Scarabelli Journal: Mol Cell Endocrinol Date: 2010-04-21 Impact factor: 4.102
Authors: Christos E Nerantzis; Spyridon N Koulouris; Soultana K Marianou; Socrates C Pastromas; Philipos N Koutsaftis; Emmanuel B Agapitos Journal: J Forensic Sci Date: 2011-03-01 Impact factor: 1.832
Authors: M Yoshida-Hiroi; M J Bradbury; G Eisenhofer; N Hiroi; W W Vale; G E Novotny; H G Hartwig; W A Scherbaum; S R Bornstein Journal: Mol Psychiatry Date: 2002 Impact factor: 15.992
Authors: Elena Martínez-Laorden; Javier Navarro-Zaragoza; María Victoria Milanés; María Luisa Laorden; Pilar Almela Journal: Int J Mol Sci Date: 2020-05-21 Impact factor: 5.923
Authors: Javier Navarro-Zaragoza; Clara Ros-Simó; María-Victoria Milanés; Olga Valverde; María-Luisa Laorden Journal: PLoS One Date: 2015-10-28 Impact factor: 3.240